
GJB2 MUTATIONS IN NON SYNDROMIC HEARING LOSS
IN THE REPUBLIC OF MACEDONIA Sukarova Stefanovska E1, Momirovska, A2,3, Cakar M4, Efremov GD1,* *Corresponding Author: Georgi D. Efremov, Research Center for Genetic Engineering and
Biotechnology, Macedonian Academy of Sciences and Arts, Blv. Krste Misirkov 2, 1000 Skopje,
R. Macedonia; Tel.: +389-2-32-35-411; fax: +389-2-31-15-434; E-mail: gde@manu.edu.mk page: 11
|
MATERIALS AND METHODS
There are approximately 6,000 persons with hearing loss or hearing impairment in Macedonia. Patients with hearing impairment have been ascertained through two regional otorhinolaryngology centers: Audiology Center, Clinic for Othorinolar-yngology, Medical faculty, Skopje and Association of Deaf and Hard of Hearing, Skopje, R. Macedonia. We performed molecular analyses of the GJB2 gene on DNA samples from 80 individuals with non syndromic hearing loss (NSHL) belonging to 33 affected, unrelated families. Twenty-three families were of Macedonian, six of Albanian, one Turkish and three of Gypsy origin. After informed consent was obtained and examination of complete medical histories was made, the family inheritance and audiological status were ascertained. DNA was isolated from peripheral white blood cells using a phenol/chloroform extraction, ethanol precipitation method [8].
The 35delG mutation was identified by the method described by Storm etal. [9], in which polymerase chain reaction (PCR) amplifications were performed with two sets of primers: GJB1: 5'-GTG AGG TTG TGT AAG AGT TG-3'; GJB2: 5'-CTG GTG GAG TGT TTG TTC CCA-3'; and as control sequence: GJB7 5'-CCA GGC TGC AAG AAC GTG TGC-3' and GJB9: 5'-CTC ATG TCT CCG GTA GGC CAC-3' under standard PCR conditions. The PCR products were digested with BszYI (Boeh-ringer, Mannheim, Germany) and analyzed by 2% agarose gel electrophoresis (Figure 1A).
For other aberrations in the GJB2 gene, the single strand conformation polymorphism (SSCP) method was used. Amplification of a 286 bp fragment belonging to the 5' end of the exon 2 coding sequence was performed using the following primers: GJB5 5'-TCT TTC CAG AGC AAA CCG C-3' and GJB8 5'-GAC ACG AAG ATC AGC TGC AGG-3', while a 270 bp fragment belonging to the 3' end of the GJB2 gene, was amplified using primers: GJB10 5'-GCA GCA TCT TCT TCC GGG T-3' and GJB6 5'-GGG CAA TGC GTT AAA CTG GC-3'. The SSCP was performed on the Bio-Rad DeCode System (Bio-Rad Laboratories, Hercules, CA, USA). The PCR products were loaded onto a non denaturing 12% acrylamide/Bisacrylamide (39:1) gel. After electrophoresis, the PCR fragments were visualized with silver staining of the
gel.
To identify the nucleotide substitutions responsible for altered the electrophoretic mobility detected by SSCP analysis, the PCR fragments were sequenced by BigDye sequencing kit v3.1 (PE Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions and separated on an Applied Biosystems 310 Genetic analyzer.
The presence of the deletion delD13S1830 encompassing part of the GJB6 gene was analyzed by use of three primers to simultaneously amplify the breakpoint-containing fragment and the normal GJB2 allele [10]. The primers used were: GJB6-1F 5'-AGT GAT CCA TCT GCC TCA GC-3'; GJB6-2RN 5'-GTC TGT GCT CTC TCT TTG ATC TC-3' and GJB6-3RD 5'-GGA AGG TGT GGA TCA CAG TC-3', under cycling conditions of initial denaturation of 10 min. at 95°C, followed by 30 cycles of 1 min. at 94°C, 1 min. at 60°C and 1 min. at 72°C in the Applied Biosystems 2720 thermal-cycler. The PCR fragments were analyzed by 1.5% agarose gel electrophoresis. The presence of a 478 bp fragment indicates the presence of the 342 kb deletion (Primers GJB6-1F and GJB6-3RD), while the presence of a 650 bp fragment indicates the normal allele (primers GJB6-1F and GJB6-2RN).
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|